Effect of grape products on blood pressure: a systematic review and meta-analysis of randomized controlled trials

Abstract

Previous studies have suggested that grape and its products may possess blood pressure (BP)-lowering properties. Due to inconsistencies in results, we aimed to systematically examine the effect of grape products on BP by conducting a meta-analysis of randomized controlled trials (RCTs). PubMed, Scopus, Web of Science (ISI), and Cochrane Library databases were comprehensively searched until March 2020. Human clinical trials which reported the effect of grape products supplementation on systolic BP (SBP) and diastolic BP (DBP) were included. Data were pooled using a random-effects model and expressed as a weighted mean difference (WMD) with a 95% confidence interval (CI). Twentyeight studies comprising a total of 1344 subjects were included in our metaanalysis. The overall outcome of the meta-analysis indicates that grape products consumption can significantly reduce SBP (WMD: −3.40 mmHg, 95% CI: −6.55, −0.24, p = .03, I 2 = 93.4%) and DBP (WMD: −1.69 mmHg, 95% CI: −3.12, −0.27, p = .01, I 2 = 80.4%). This meta-analysis found a moderate and statistically significant reduction for either SBP or DBP with grape products compared with controls. Additional high-quality studies are needed to further evaluate the causal conclusions.

The Role of Diet in the Prevention of Hypertension and Management of Blood Pressure: An Umbrella Review of Meta-Analyses of Interventional and Observational Studies

“…Of the high and moderate evidence quality meta-analyses, ( n = 10) and ( n = 70) were of low risk of publication bias, respectively, and the interventions under reviewed were (high quality): very-low-carbohydrate ketogenic diet compared with low-fat diet (DBP) [ 79 ], DASH diet compared with controls [ 88 ], flaxseed compared with controls [ 89 ], multivitamin and multimineral compared with controls (DBP) [ 90 ], products with live bacteria compared with controls [ 91 ], grape and its products compared with controls [ 92 ], nitrates compared with controls (SBP) [ 93 ], urinary potassium compared with controls [ 94 ], and steviol glycoside compared with controls (DBP) [ 95 ].…”

“…The NutriGrade ratings for a dietary factor were often the same for SBP and DBP and the evidence was generally for populations of mixed health statuses, the exceptions were specified. We summarized the effects of diet exposure on blood pressure and risk of hypertension in Table 1 [ [11] , [13] , [15] , [17] , [18] , [19] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [62] , [66] , [67] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [79] , [80] , [81] , [82] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] , [101] , [102] , [103] , [104] , …”

“…There was high-quality evidence showing reduction in SBP and DBP with grape intake and its products [ 92 ] ( Figure 12 A and B). There was moderate-quality evidence showing significant reductions in SBP and DBP with intakes of grape seed extract (SBP) [ 192 ], anthocyanins (berries, red grapes, and red wine) (SBP) [ 193 ], quercetin (DBP) [ 194 ], flavanols [ 46 ], and proanthocyanidins [ 87 ].…”

Effect of grape‐derived products on the serum levels of enzymes mainly produced by the liver: A systematic review and meta‐analysis of parallel randomized controlled trials

“…This fruit has many active polyphenolic compounds, especially resveratrol (Rodriguez‐Lopez et al, 2022; Vislocky & Fernandez, 2010). Recent studies have shown that grapes can be useful in improving lipid profiles (Lupoli et al, 2020), glycemic indices (da Silva et al, 2023), blood pressure (Asbaghi et al, 2021), and some inflammatory markers (Foshati et al, 2021). Although various studies have examined the effect of grape product intervention on liver enzymes, the findings have been inconsistent (Hokayem et al, 2013; Kaliora et al, 2016; Tomé‐Carneiro et al, 2013).…”